Lannett Emerges from Bankruptcy with Refocused Strategy

Lannett Company, now privately held, settles a major antitrust case for $13.77M, focuses on niche generics after restructuring eliminated $600M in debt.

Following the completion of its Chapter 11 proceedings, Lannett Company has begun operating as a privately held entity. The generic drug manufacturer is now under the control of its former creditors, with its publicly traded shares having been canceled as part of the financial restructuring. Management is directing its efforts toward implementing a fresh corporate direction and resolving outstanding legal matters.

Legal Settlements and Future Proceedings

A significant component of Lannett's new chapter involves settling protracted litigation. In February 2026, the company reached a resolution in a wide-ranging antitrust case that has impacted the entire generic pharmaceutical industry. As part of a settlement with 48 U.S. states and territories, Lannett agreed to pay approximately $13.77 million.

A key stipulation of this agreement mandates the firm's ongoing cooperation in active lawsuits against other companies and executives within the sector. Industry observers view this move as a necessary step to mitigate legal risks for daily operations and to provide stability for the new ownership.

However, the legal fallout from industry-wide price-fixing allegations continues. A major trial related to these matters is anticipated in Hartford, Connecticut, by the end of 2026. In the interim, Lannett is implementing new, court-mandated compliance programs designed to prevent future regulatory conflicts.

A Cleaner Balance Sheet and Niche Focus

The restructuring, finalized in June 2023, allowed the company to eliminate roughly $600 million in debt. With this strengthened financial position, Lannett is sharpening its strategic focus on more complex, high-value generic products.

Its revitalized pipeline centers on specialized franchises, including insulin formulations as well as medications for treating ADHD and respiratory conditions. This shift toward higher-margin niche products is a strategic response to the intense price competition common in the generic drug market. Developing complex therapeutics is seen as a critical driver for growth amid persistent industry pricing pressures.